Global Flumazenil Market, by Dose (5 ml, 10 ml), by Application (Anti – Sedation, Reversing Drowsiness, Others (Hepatic Encephalopathy, Cirrhosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 20.528 Million in 2022 and is expected to exhibit a CAGR of 2.8% during the forecast period (2022-2030).
Regulatory authorities are updating guidelines for the flumazenil dosage used for the management of benzodiazepine overdose, which is expected to drive growth of the global flumazenil market. For instance, according to updated data on May 8, 2022, by National Center for Biotechnology Information (NCBI), the U.S. Food and Drug Administration has shared the guidelines for management of benzodiazepine overdose with use of flumazenil injection. Initially for 30 second 0.2 mg of flumazenil should be given intravenously to adults. If the wanted level of consciousness is not gained after 30 seconds, than additional dose of 0.3 mg over 30 seconds should be given intravenously.
Regulatory approval for the use of flumazenil is expected to propel growth of the global flumazenil market, over the forecast period. For instance, according to data updated on May 8, 2022 by. National Center for Biotechnology Information, U.S. Food and Drug Administration had approved the use of flumazenil as reversal drug for benzodiazepine overdose clinically. Benzodiazepines are a class of drugs that treat insomnia, anxiety, pain, and seizures.
Global Flumazenil Market- Impact of Coronavirus (COVID – 19) Pandemic
The coronavirus disease (COVID-19) pandemic is expected to hamper growth of the global flumazenil market over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after August 3, 2022. Therefore, as of August 3, 2022, around 578 million cases and over 6.4 million deaths have been reported.
Decline in clinical trials for new drugs during COVID-19 pandemic is expected to hamper growth of the global flumazenil market. Due to need for developing new vaccines to treat COVID-19, several forthcoming and ongoing clinical trials for other diseases were stopped globally. The disruption of clinical trials for other drugs has also disturbed the clinical trials for flumazenil, which has hampered growth of the global flumazenil market during COVID-19 pandemic.
Browse 37 Market Data Tables and 45 Figures spread through 408 Pages and in-depth TOC on Global Flumazenil Market, by Dose (5 ml, 10 ml), by Application (Anti – Sedation, Reversing Drowsiness, Others (Hepatic Encephalopathy, Cirrhosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the Flumazenil market, click the link below:
https://www.coherentmarketinsights.com/market-insight/flumazenil-market-5187
Newly updated and published data related to use of flumazenil is expected to propel growth of the global flumazenil market, over the forecast period. For instance, on May 8, 2022, National Institute of Health, U.S. had published updated data on flumazenil. In published data NIH had highlighted about the outline for using flumazenil, identified the mechanism of action of flumazenil as well as reviewed professional team strategies for developing flumazenil therapy. This would help market players to understand more details about flumazenil and the same would help them in improving the development in flumazenil therapy. This is expected to drive growth of the flumazenil market.
Key Takeaways of the Flumazenil Market:
- Global flumazenil market is expected to exhibit a CAGR of 2.8% over the forecast period (2022-2030), owing to growth in potential markets, especially in Europe. While North America accounted for the major market share.
- Regulatory authorities are updating guidelines for the use of flumazenil, which is expected to drive growth of the global flumazenil market over the forecast period. For instance, according to updated data on May 8, 2022, by National Institute of Health, the U.S. Food and Drug Administration has updated guidelines for the use of flumazenil in children such as flumazenil is not recommended for the children who have a problem which shows other indication than conscious sedation. Flumazenil should be only directed to children below the age of 1 year if benzodiazepine overdose has been evaluated up against the benefits of treatment. Based on the dose and period of effect of the benzodiazepine employed, the patient should be checked for a suitable period of time. The flumazenil should not be given to a patient if sleep is caused by some other drug except benzodiazepines.
- Major players operating in the global flumazenil market include Hoffmann La Roche, Akorn-Strides, LLC, Sandoz Canada Incorporated, Fresenius Kabi USA, LLC, Mylan Pharmaceuticals, Genentech, Inc., General Injectables & Vaccines Inc, Sina Health Inc, West Ward Pharmaceutical, HF Acquisition Co. LLC, DBA HealthFirst, Hikma Farmaceutica, Pfizer Laboratories Div Pfizer Inc., Physicians Total Care, Inc., and Bedford Pharmaceuticals
